The effect of human recombinant epidermal growth factor in the treatment of diabetic foot ulcers
Objectives. Diabetic foot ulcer (DFU) is one of the most important and common complication of type 2 diabetes mellitus (T2DM). A new therapy, consisting of intralesional administration of human recombinant epidermal growth factor (hrEGF), has been suggested to accelerate wound healing and prevent am...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Digital ProScholar Media
2022-05-01
|
| Series: | Journal of Clinical and Investigative Surgery |
| Subjects: | |
| Online Access: | https://www.e-repository.org/jcis/7/1/7.pdf |
| _version_ | 1817981029875449856 |
|---|---|
| author | Mehmet Kadir Bartın Gokalp Okut |
| author_facet | Mehmet Kadir Bartın Gokalp Okut |
| author_sort | Mehmet Kadir Bartın |
| collection | DOAJ |
| description | Objectives. Diabetic foot ulcer (DFU) is one of the most important and common complication of type 2 diabetes mellitus (T2DM). A new therapy, consisting of intralesional administration of human recombinant epidermal growth factor (hrEGF), has been suggested to accelerate wound healing and prevent amputations. The effect of hrEGF on DFU treatment was investigated in this study. Materials and Methods. 20 patients with DFU were included in this study, all of whom were receiving insulin treatment for T2DM. In addition, they received intralesional therapy with a dose of 75 μgr of hrEGF, three times a week. Results. In 18 patients, complete granulation response was achieved in approximately 3,3 weeks. There were 2 cases of recurrence at 6 months after EGF treatment. Between 6 and 12 doses of epidermal growth factor were used for this study. The most common side effects were tremor, chills, pain and burning at the site of administration. Conclusions. Our study shows that intralesional administration of hrEGF in T2DM can prevent amputations in DFU and also accelerate wound healing. Thus, intralesional application of hrEGF should be an option for standard care, as a second line of treatment (given its cost-effectiveness) when appropriate. |
| first_indexed | 2024-04-13T23:00:36Z |
| format | Article |
| id | doaj.art-485193aad50a4caea7a76aac7954a05f |
| institution | Directory Open Access Journal |
| issn | 2559-5555 |
| language | English |
| last_indexed | 2024-04-13T23:00:36Z |
| publishDate | 2022-05-01 |
| publisher | Digital ProScholar Media |
| record_format | Article |
| series | Journal of Clinical and Investigative Surgery |
| spelling | doaj.art-485193aad50a4caea7a76aac7954a05f2022-12-22T02:25:50ZengDigital ProScholar MediaJournal of Clinical and Investigative Surgery2559-55552022-05-0171384210.25083/2559.5555/7.1.7The effect of human recombinant epidermal growth factor in the treatment of diabetic foot ulcersMehmet Kadir Bartın0Gokalp Okut1DEPARTMENT OF GENERAL SURGERY, HEALTH SCIENCE UNIVERSITY EDUCATION AND RESEARCH HOSPITAL, VAN, TURKEYDEPARTMENT OF GENERAL SURGERY, HEALTH SCIENCE UNIVERSITY EDUCATION AND RESEARCH HOSPITAL, VAN, TURKEYObjectives. Diabetic foot ulcer (DFU) is one of the most important and common complication of type 2 diabetes mellitus (T2DM). A new therapy, consisting of intralesional administration of human recombinant epidermal growth factor (hrEGF), has been suggested to accelerate wound healing and prevent amputations. The effect of hrEGF on DFU treatment was investigated in this study. Materials and Methods. 20 patients with DFU were included in this study, all of whom were receiving insulin treatment for T2DM. In addition, they received intralesional therapy with a dose of 75 μgr of hrEGF, three times a week. Results. In 18 patients, complete granulation response was achieved in approximately 3,3 weeks. There were 2 cases of recurrence at 6 months after EGF treatment. Between 6 and 12 doses of epidermal growth factor were used for this study. The most common side effects were tremor, chills, pain and burning at the site of administration. Conclusions. Our study shows that intralesional administration of hrEGF in T2DM can prevent amputations in DFU and also accelerate wound healing. Thus, intralesional application of hrEGF should be an option for standard care, as a second line of treatment (given its cost-effectiveness) when appropriate.https://www.e-repository.org/jcis/7/1/7.pdfdiabetic foot ulcersdiabetes mellitusepithelial growth factor |
| spellingShingle | Mehmet Kadir Bartın Gokalp Okut The effect of human recombinant epidermal growth factor in the treatment of diabetic foot ulcers Journal of Clinical and Investigative Surgery diabetic foot ulcers diabetes mellitus epithelial growth factor |
| title | The effect of human recombinant epidermal growth factor in the treatment of diabetic foot ulcers |
| title_full | The effect of human recombinant epidermal growth factor in the treatment of diabetic foot ulcers |
| title_fullStr | The effect of human recombinant epidermal growth factor in the treatment of diabetic foot ulcers |
| title_full_unstemmed | The effect of human recombinant epidermal growth factor in the treatment of diabetic foot ulcers |
| title_short | The effect of human recombinant epidermal growth factor in the treatment of diabetic foot ulcers |
| title_sort | effect of human recombinant epidermal growth factor in the treatment of diabetic foot ulcers |
| topic | diabetic foot ulcers diabetes mellitus epithelial growth factor |
| url | https://www.e-repository.org/jcis/7/1/7.pdf |
| work_keys_str_mv | AT mehmetkadirbartın theeffectofhumanrecombinantepidermalgrowthfactorinthetreatmentofdiabeticfootulcers AT gokalpokut theeffectofhumanrecombinantepidermalgrowthfactorinthetreatmentofdiabeticfootulcers AT mehmetkadirbartın effectofhumanrecombinantepidermalgrowthfactorinthetreatmentofdiabeticfootulcers AT gokalpokut effectofhumanrecombinantepidermalgrowthfactorinthetreatmentofdiabeticfootulcers |